Search results for "death"

showing 10 items of 1744 documents

Impact of pulmonary embolism on in-hospital mortality of patients with ischemic stroke

2020

Pulmonary embolism (PE) is a frequent complication in immobile stroke patients and an important cause of death in stroke patients. We aimed to investigate predictors of PE and the impact of PE on survival of ischemic stroke patients.Patients were selected by screening the German nationwide inpatient sample (2005-2017) for ischemic stroke (ICD-code I63) and stratified for occurrence of PE (ICD-code I26). Impact of PE on mortality and predictors for PE in ischemic stroke patients were analysed.Overall, 2,914,546 patients were hospitalized due to ischemic stroke (50.5% females; 69.3% aged ≥70 years) in Germany 2005-2017. Among these, 0.4% had PE and 7.2% died during hospitalization. In-hospita…

MaleResuscitationmedicine.medical_specialtymedicine.medical_treatmentBrain Ischemia03 medical and health sciences0302 clinical medicineGermanyInternal medicineHumansMedicineHospital Mortalitycardiovascular diseases030212 general & internal medicineAgedIschemic StrokeCause of deathIn hospital mortalitybusiness.industryMortality rateThrombolysismedicine.diseasePulmonary embolismStrokeNeurologyIschemic strokeCardiologyFemaleNeurology (clinical)Pulmonary EmbolismbusinessComplication030217 neurology & neurosurgeryJournal of the Neurological Sciences
researchProduct

Occurrence of Retinal Ganglion Cell Loss via Autophagy and Apoptotic Pathways in an Autoimmune Glaucoma Model

2020

In glaucoma, an apoptotic death of retinal ganglion cells (RGCs) has been shown. However, little is known about other cell death mechanisms, like autophagy or necrosis. Therefore, we investigated these mechanisms in addition to antibody deposits in an experimental autoimmune glaucoma model.Rats were immunized with a retinal ganglion cell-layer homogenate (RGA), while controls received sodium chloride. Untreated rats served as natїve group. After seven weeks, retinal cross-sections were stained with antibodies against RGCs (Brn-3a), apoptosis (cleaved caspase 2, cleaved caspase 3 as well as caspase 3, 8, and 9), autophagy (LC3BII and LAMP1), and necrosis (RIPK3) followed by cell counts. Auto…

MaleRetinal Ganglion CellsProgrammed cell deathNecrosisgenetic structuresGlaucomaApoptosisAutoantigensRetinal ganglionAutoimmune Diseases03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineMicroscopy Electron TransmissionAutophagymedicineAnimalsAutoantibodiesCaspase 8biologyCaspase 3business.industryAutophagyLysosome-Associated Membrane GlycoproteinsGlaucomamedicine.diseaseCaspase 9eye diseasesSensory SystemsRatsDisease Models AnimalOphthalmologymedicine.anatomical_structureMicroscopy FluorescenceRetinal ganglion cellRats Inbred LewApoptosisImmunoglobulin G030221 ophthalmology & optometryCancer researchbiology.proteinsense organsAntibodymedicine.symptombusinessMicrotubule-Associated Proteins030217 neurology & neurosurgeryCurrent Eye Research
researchProduct

Retinal ganglion cell loss is accompanied by antibody depositions and increased levels of microglia after immunization with retinal antigens.

2012

BackgroundAntibodies against retinal and optic nerve antigens are detectable in glaucoma patients. Recent studies using a model of experimental autoimmune glaucoma demonstrated that immunization with certain ocular antigens causes an immun-mediated retinal ganglion cell loss in rats.Methodology/principal findingsRats immunized with a retinal ganglion cell layer homogenate (RGA) had a reduced retinal ganglion cell density on retinal flatmounts (p = 0.007) and a lower number of Brn3(+) retinal ganglion cells (p = 0.0001) after six weeks. The autoreactive antibody development against retina and optic nerve was examined throughout the study. The levels of autoreactive antibodies continuously in…

MaleRetinal Ganglion Cellsgenetic structuresGlaucomaAutoimmunityImmune PrivilegeAutoantigenschemistry.chemical_compoundNeurobiology of Disease and RegenerationImmune ResponseMultidisciplinaryCell DeathMicrogliaQRAnimal ModelsImmunizationsmedicine.anatomical_structureNeurologyRetinal ganglion cellOptic nerveMedicineMicrogliaImmunohistochemical AnalysisResearch ArticleHistologyImmune CellsScienceImmunologyImmunoglobulinsModel OrganismsAntigenmedicineAnimalsAntibody-Producing CellsBiologyAutoantibodiesRetinabusiness.industryImmunityAutoantibodyGlaucomaRetinalbiochemical phenomena metabolism and nutritionmedicine.diseaseeye diseasesRatsOphthalmologychemistryRats Inbred LewImmunologyImmunologic TechniquesNeuro-OphthalmologyRatClinical ImmunologyImmunizationsense organsbusinessNeurosciencePLoS ONE
researchProduct

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery di…

2008

Summary. Background: Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis. Results on the association between TAFI levels and the risk of coronary artery disease (CAD) are inconsistent. Objectives: We investigated the association between TAFI levels and the risk of cardiovascular events in CAD. Patients/Methods: 1668 individuals with angiographically proven CAD at baseline were followed for a median of 2.3 years, as part of the prospective AtheroGene cohort. Fifty-six deaths from cardiovascular (CV) causes and 35 non-fatal CV events were observed. Results: At baseline, three TAFI measurements were available: one evaluating the total amount of TAFI (t-TAFI), one measuri…

MaleRiskCarboxypeptidase B2medicine.medical_specialtymedicine.medical_treatmentCoronary Artery DiseaseCoronary artery diseaseRisk FactorsInternal medicineFibrinolysismedicineHumansMyocardial infarctionAgedProportional Hazards Modelsbusiness.industryUnstable anginaProportional hazards modelHazard ratioHematologyMiddle Agedmedicine.diseaseCarboxypeptidase BDeath Sudden CardiacCohortCardiologyFemalebusinessProtein Cmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Geographical Variability in Mortality in Urban Areas: A Joint Analysis of 16 Causes of Death.

2021

The authors acknowledge the support of the research grants PI16/00670, PI16/00755, PI16/01004, PI16/01187, PI16/01273, PI16/01281, and PI18/01313 of Instituto de Salud Carlos III, co-funded with FEDER grants.

MaleRiskHealth Toxicology and Mutagenesisurban areasJoint analysis01 natural sciencesArticle010104 statistics & probability03 medical and health sciences0302 clinical medicineCause of Deathgeographical inequalitiesHumans030212 general & internal medicine0101 mathematicsCitiesMortalitySocioeconomicsmultivariate disease mappingGeographyPublic Health Environmental and Occupational HealthRmortalityGeographySocioeconomic FactorsMedicineEnfermeríaFemaleGeographical inequalities
researchProduct

Inequity in palliative care service full utilisation among patients with advanced cancer: a retrospective Cohort study.

2020

Background: Advanced cancer patients often die in hospital after receiving needless, aggressive treatment. Although palliative care improves symptom management, barriers to accessing palliative care services affect its utilisation, and such disparities challenge the equitable provision of palliative care. This study aimed to identify which factors are associated with inequitable palliative care service utilisation among advanced cancer patients by applying the Andersen Behavioural Model of Health Services Use.Material and methods: This was a retrospective cohort study using administrative healthcare data. A total of 13,656 patients residing in the Lazio region of Italy, who died of an advan…

MaleRural Populationmedicine.medical_specialtyPalliative careUrban PopulationMEDLINEHealth Services AccessibilityWhite People030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinenursingCause of DeathNeoplasmsadvance cancerMedicineHumansRadiology Nuclear Medicine and imagingHospital MortalityRegistriesHealthcare DisparitiesIntensive care medicineSurvival rateCause of deathAgedRetrospective StudiesService (business)Aged 80 and overHealth Services Needs and Demandbusiness.industrySymptom managementPalliative CareAge FactorsRetrospective cohort studyHematologyGeneral MedicineMiddle AgedAdvanced cancerSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatrichePatient DischargeSurvival RateinequityLogistic ModelsOncologyItaly030220 oncology & carcinogenesisEducational StatusFemalebusinessActa oncologica (Stockholm, Sweden)
researchProduct

Convergent sets of data from in vivo and in vitro methods point to an active role of Hsp60 in chronic obstructive pulmonary disease pathogenesis.

2011

BackgroundIt is increasingly clear that some heat shock proteins (Hsps) play a role in inflammation. Here, we report results showing participation of Hsp60 in the pathogenesis of chronic obstructive pulmonary diseases (COPD), as indicated by data from both in vivo and in vitro analyses.Methods and resultsBronchial biopsies from patients with stable COPD, smoker controls with normal lung function, and non-smoker controls were studied. We quantified by immunohistochemistry levels of Hsp10, Hsp27, Hsp40, Hsp60, Hsp70, Hsp90, and HSF-1, along with levels of inflammatory markers. Hsp10, Hsp40, and Hsp60 were increased during progression of disease. We found also a positive correlation between th…

MaleSTRESSPulmonologyChronic Obstructive Pulmonary DiseasesNeutrophilsBiopsyGene ExpressionCD8-Positive T-Lymphocytesmedicine.disease_causeBiochemistryEpitheliumPulmonary function testingPathogenesisACTIVATIONPulmonary Disease Chronic ObstructiveMolecular Cell BiologyLungCOPDMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionCOPD Hsp60QRCOPD heat shock proteins inflammationMiddle AgedImmunohistochemistrymedicine.anatomical_structureEXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITISMedicineFemalemedicine.symptomInflammation MediatorsSPINAL-CORDResearch ArticleEXPRESSIONanimal structuresCOPD; heat shock proteins; inflammationScienceImmunologyMolecular Sequence DataInflammationBronchichemical and pharmacologic phenomenaHEAT-SHOCK-PROTEIN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS ACUTE LUNG INJURY SPINAL-CORD CELL-DEATH KAPPA-B HEAT-SHOCK-PROTEIN-60 STRESS EXPRESSION ACTIVATIONKAPPA-BBiologyHEAT-SHOCK-PROTEINMicrobiologycomplex mixturesCell LineACUTE LUNG INJURYMolecular GeneticsIn vivoStress PhysiologicalHeat shock proteinmedicineGeneticsHumansCOPDRNA MessengerBiologyAgedLungMucous MembraneBase SequenceSettore BIO/16 - Anatomia UmanaMacrophagesfungiImmunityTranscription Factor RelAProteinsComputational BiologyChaperonin 60medicine.diseaseChaperone Proteinsrespiratory tract diseasesGene Expression RegulationCELL-DEATHHEAT-SHOCK-PROTEIN-60inflammationImmunologyheat shock proteinsClinical ImmunologyOxidative stressBiomarkers
researchProduct

Cycloastragenol as an Exogenous Enhancer of Chondrogenic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells. A Morphological Study

2020

Stem cell therapy and tissue engineering represent a promising approach for cartilage regeneration. However, they present limits in terms of mechanical properties and premature de-differentiation of engineered cartilage. Cycloastragenol (CAG), a triterpenoid saponin compound and a hydrolysis product of the main ingredient in Astragalus membranaceous, has been explored for cartilage regeneration. The aim of this study was to investigate CAG&rsquo

MaleSettore BIO/17 - IstologiaSapogeninsTime Factorscycloastragenolhuman adipose-derived mesenchymal stem cellsArticleExtracellular matrixchemistry.chemical_compoundTissue engineeringchondrocyte phenotypemedicineHumansCycloastragenolAggrecanscartilage regenerationCell Shapelcsh:QH301-705.5AggrecanCells CulturedGlycoproteinsGlycosaminoglycansCell DeathChemistryCartilageRegeneration (biology)Mesenchymal stem cellCell DifferentiationMesenchymal Stem CellsSOX9 Transcription FactorGeneral MedicineMiddle AgedChondrogenesisCell biologycartilage regeneration; chondrocyte phenotype; cycloastragenol; human adipose-derived mesenchymal stem cells; hypertrophy; tissue engineeringmedicine.anatomical_structurelcsh:Biology (General)tissue engineeringFemaleCollagenhypertrophyChondrogenesiscartilage regeneration; chondrocyte phenotype; cycloastragenol; human adipose-derived mesenchymal stem cells; hypertrophy; tissue engineering; Aggrecans; Cell Death; Cell Differentiation; Cell Shape; Cells Cultured; Chondrogenesis; Collagen; Female; Glycoproteins; Glycosaminoglycans; Humans; Male; Mesenchymal Stem Cells; Middle Aged; SOX9 Transcription Factor; Sapogenins; Time FactorsCells
researchProduct

Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study

2018

Chronic obstructive pulmonary disease (COPD) increases the risk of mortality in non-valvular atrial fibrillation (NVAF) patients. Data on the relationship of COPD to major cardiovascular events (MACE) in AF have not been defined. The aim of the study is to assess the predictive value of COPD on incident MACE in NVAF patients over a 3-year follow-up. In the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study (ARAPACIS) cohort, we evaluate the impact of COPD on the following clinical endpoints: MACE (including vascular death, fatal/non-fatal MI and stroke/TIA), cardiovascular (CV) death and all-cause mortality. Among 2027 NVAF patients, pati…

MaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologyPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsMajor cardiovascular eventCause of DeathRisk of mortalityPrevalenceMedicine030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyStrokeCause of deathCOPDChronic obstructive pulmonary diseaseIncidenceHazard ratioAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular events; Aged; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Endpoint Determination; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Predictive Value of Tests; Prevalence; Prospective Studies; Pulmonary Disease Chronic Obstructive; Registries; Risk Factors; Internal Medicine; Emergency MedicineAtrial fibrillationAtrial fibrillation Cardiovascular mortality Chronic obstructive pulmonary disease Major cardiovascular eventsItalyCardiovascular DiseasesCardiologyEmergency MedicineFemaleSettore SECS-S/01 - Statisticamedicine.medical_specialtyChronic ObstructiveCardiovascular mortalityEndpoint DeterminationAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular events; Aged; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Endpoint Determination; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Predictive Value of Tests; Prevalence; Prospective Studies; Pulmonary Disease Chronic Obstructive; Registries; Risk FactorsSocio-culturalePulmonary Disease03 medical and health sciencesPredictive Value of TestsInternal medicineInternal MedicineHumanscardiovascular diseasesAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular eventsAgedbusiness.industryMajor cardiovascular eventsmedicine.diseaseAtrial fibrillationAtrial fibrillation; Cardiovascular mortality; Chronic obstructive pulmonary disease; Major cardiovascular events; Internal Medicine; Emergency MedicinebusinessMaceFollow-Up Studies
researchProduct

Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials.

2015

Background Randomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe+simvastatin, on mortality and morbidity outcomes. Methods and Findings We searched for RCT on Ezetimibe using MEDLINE, CCTR, EMBASE, ClinicalTrials.gov databases up to December 2013, Merck and Novartis online registers, and personal communications. Two authors independently selected trials fulfilling these criteria: RCTs comparing Ezetimibe±statin or another lipid-lowering drug against placebo, or against the same lipid-lowering drug at the same …

MaleSimvastatinmedicine.medical_specialtylcsh:MedicineComorbidityPharmacologyPlacebolaw.inventionEzetimibeRandomized controlled triallawCardiovascular DiseaseCause of DeathInternal medicineAnticholesteremic AgentmedicineHumansAdverse effectlcsh:ScienceStrokeAgedRandomized Controlled Trials as TopicCause of deathMultidisciplinarybusiness.industryAnticholesteremic Agentslcsh:RMiddle AgedEzetimibemedicine.diseaseTreatment OutcomeCardiovascular DiseasesSimvastatinMeta-analysisDrug Therapy CombinationFemalelcsh:QbusinessResearch ArticleHumanmedicine.drugPLoS ONE
researchProduct